Telomerase inhibitory therapies, heterochromatin silence-mechanism targeted therapies, and G4-destabilizing therapies are promising therapeutic targets for gliomas with ATRX or TERTp mutation10,11. This evidence concerns the gene ATRX and central nervous system cancer.